T-0632 | CAS#169042-78-8 | CCKA Receptor Antagonist

MedKoo Cat#: 558246 | Name: T-0632

Description:

WARNING: This product is for research use only, not for human or veterinary use.

T-0632 is a novel potent and selective CCKA receptor antagonist.

Chemical Structure

T-0632

CAS#169042-78-8

Theoretical Analysis

MedKoo Cat#: 558246

Name: T-0632

CAS#: 169042-78-8

Chemical Formula: C29H27FN2O5

Exact Mass: 502.1904

Molecular Weight: 502.54

Elemental Analysis: C, 69.31; H, 5.42; F, 3.78; N, 5.57; O, 15.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

T-0632, T 0632, T0632

IUPAC/Chemical Name

3-[(3S)-1-(2-fluorophenyl)-6-methoxy-2-oxo-3-(1,2,3,4-tetrahydronaphthalene-2-carbonylamino)indol-3-yl]propanoic acid

InChi Key

RORYEMYJJAIHBK-PRTIIRGTSA-N

InChi Code

InChI=1S/C29H27FN2O5/c1-37-21-12-13-22-25(17-21)32(24-9-5-4-8-23(24)30)28(36)29(22,15-14-26(33)34)31-27(35)20-11-10-18-6-2-3-7-19(18)16-20/h2-9,12-13,17,20H,10-11,14-16H2,1H3,(H,31,35)(H,33,34)/t20?,29-/m0/s1

SMILES Code

O=C(O)CC[C@@]1(NC(C2CC3=C(C=CC=C3)CC2)=O)C(N(C4=CC=CC=C4F)C5=C1C=CC(OC)=C5)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 502.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tibaduiza EC, Chen C, Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem. 2001 Oct 12;276(41):37787-93. Epub 2001 Aug 9. PubMed PMID: 11498540. 2: Dong M, Vattelana AM, Lam PC, Orry AJ, Abagyan R, Christopoulos A, Sexton PM, Haines DR, Miller LJ. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding. Mol Pharmacol. 2015 Jan;87(1):130-40. doi: 10.1124/mol.114.095430. Epub 2014 Oct 15. PubMed PMID: 25319540; PubMed Central PMCID: PMC4279081. 3: Niederau C, Grendell JH. Role of cholecystokinin in the development and progression of acute pancreatitis and the potential of therapeutic application of cholecystokinin receptor antagonists. Digestion. 1999;60 Suppl 1:69-74. PubMed PMID: 10026436. 4: Taniguchi H, Yomota E, Kume E, Shikano T, Endo T, Nagasaki M. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12. PubMed PMID: 9074944.